Wedbush Has Lowered Expectations for Aprea Therapeutics (NASDAQ:APRE) Stock Price

Aprea Therapeutics (NASDAQ:APRE) had its target price dropped by research analysts at Wedbush from $7.00 to $6.00 in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm currently has an “outperform” rating on the stock.

A number of other research firms have also recently commented on APRE. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Oppenheimer started coverage on Aprea Therapeutics in a report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price objective on the stock. HC Wainwright cut their price objective on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.07.

Aprea Therapeutics Stock Performance

Shares of APRE opened at $0.93 on Thursday. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.22. The business’s fifty day moving average is $0.82 and its 200-day moving average is $0.91. The firm has a market cap of $11.51 million, a price-to-earnings ratio of -0.60 and a beta of 1.48.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.The company had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, research analysts forecast that Aprea Therapeutics will post -0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in APRE. Jane Street Group LLC acquired a new position in shares of Aprea Therapeutics in the 4th quarter valued at about $40,000. DRW Securities LLC acquired a new position in shares of Aprea Therapeutics in the 4th quarter valued at about $103,000. Finally, AIGH Capital Management LLC lifted its stake in shares of Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after purchasing an additional 645,000 shares during the period. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.